RESUMEN
OBJECTIVES: To evaluate the combination of a culture medium employing glucoamylase-mediated glucose reléase from a gluco-polysaccharide and an E. coli strain engineered in its glucose transport system for improving plasmid DNA (pDNA) production. RESULTS: The production of pDNA was tested using E. coli DH5α grown in shake-flasks and the recently developed VH33 Δ(recA deoR)-engineered strain, which utilizes glucose more efficiently than wild type strains. Three glucoamylase concentrations for releasing glucose from the polysaccharide carbon source were used: 1, 2 and 3 U l(-1). Both strains reached similar cell densities ranging from 5 to 8.8 g l(-1) under the different conditions. The highest pDNA yields on biomass (YpDNA/X) for both strains were obtained when 3 U enzyme l(-1)were used. Under these conditions, 35 ± 3 mgof pDNA l(-1) were produced by DH5α after 24 h of culture. Under the same conditions, the engineered strain produced 66 ± 1 mgpDNAl(-1) after 20 h. pDNA supercoiled fractionswere close to 80 % for both strains. CONCLUSIONS: The pDNA concentration achieved by the engineered E. coli was 89 % higher than that of DH5α. The combination of the engineered strain and enzyme-controlled glucose release is an attractive alternative for pDNA production in shake-flasks.
Asunto(s)
Escherichia coli/crecimiento & desarrollo , Glucosa/metabolismo , Plásmidos/genética , Técnicas de Cultivo Celular por Lotes , Escherichia coli/genética , Proteínas de Escherichia coli/genética , Ingeniería Metabólica , Mutación , Vacunas de ADN/biosíntesisRESUMEN
BACKGROUND: The bacterium Escherichia coli can be grown employing various carbohydrates as sole carbon and energy source. Among them, glucose affords the highest growth rate. This sugar is nowadays widely employed as raw material in industrial fermentations. When E. coli grows in a medium containing non-limiting concentrations of glucose, a metabolic imbalance occurs whose main consequence is acetate secretion. The production of this toxic organic acid reduces strain productivity and viability. Solutions to this problem include reducing glucose concentration by substrate feeding strategies or the generation of mutant strains with impaired glucose import capacity. In this work, a collection of E. coli strains with inactive genes encoding proteins involved in glucose transport where generated to determine the effects of reduced glucose import capacity on growth rate, biomass yield, acetate and production of an experimental plasmid DNA vaccine (pHN). RESULTS: A group of 15 isogenic derivatives of E. coli W3110 were generated with single and multiple deletions of genes encoding glucose, mannose, beta-glucoside, maltose and N-acetylglucosamine components of the phosphoenolpyruvate:sugar phosphotransferase system (PTS), as well as the galactose symporter and the Mgl galactose/glucose ABC transporter. These strains were characterized by growing them in mineral salts medium supplemented with 2.5 g/L glucose. Maximum specific rates of glucose consumption (qs) spanning from 1.33 to 0.32 g/g h were displayed by the group of mutants and W3110, which resulted in specific growth rates ranging from 0.65-0.18 h(-1). Acetate accumulation was reduced or abolished in cultures with all mutant strains. W3110 and five selected mutant derivatives were transformed with pHN. A 3.2-fold increase in pHN yield on biomass was observed in cultures of a mutant strain with deletion of genes encoding the glucose and mannose PTS components, as well as Mgl. CONCLUSIONS: The group of E. coli mutants generated in this study displayed a reduction or elimination of overflow metabolism and a linear correlation between qs and the maximum specific growth rate as well as the acetate production rate. By comparing DNA vaccine production parameters among some of these mutants, it was possible to identify a near-optimal glucose import rate value for this particular application. The strains employed in this study should be a useful resource for studying the effects of different predefined qs values on production capacity for various biotechnological products.
Asunto(s)
Escherichia coli/metabolismo , Vacunas de ADN/biosíntesis , Ácido Acético/metabolismo , Biomasa , Proteínas de Unión al Calcio/genética , Proteínas de Unión al Calcio/metabolismo , Escherichia coli/genética , Escherichia coli/crecimiento & desarrollo , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/metabolismo , Glucosa/metabolismo , Proteínas Facilitadoras del Transporte de la Glucosa/genética , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Cinética , Proteínas de Transporte de Monosacáridos/genética , Proteínas de Transporte de Monosacáridos/metabolismo , Proteínas de Unión Periplasmáticas/genética , Proteínas de Unión Periplasmáticas/metabolismo , Sistema de Fosfotransferasa de Azúcar del Fosfoenolpiruvato/genética , Sistema de Fosfotransferasa de Azúcar del Fosfoenolpiruvato/metabolismo , Plásmidos/genética , Plásmidos/metabolismoRESUMEN
BACKGROUND: Plasmid DNA (pDNA) is a promising molecule for therapeutic applications. pDNA is produced by Escherichia coli in high cell-density cultivations (HCDC) using fed-batch mode. The typical limitations of such cultivations, including metabolic deviations like aerobic acetate production due to the existence of substrate gradients in large-scale bioreactors, remain as serious challenges for fast and effective pDNA production. We have previously demonstrated that the substitution of the phosphotransferase system by the over-expressed galactose permease for glucose uptake in E. coli (strain VH33) allows efficient growth, while strongly decreases acetate production. In the present work, additional genetic modifications were made to VH33 to further improve pDNA production. Several genes were deleted from strain VH33: the recA, deoR, nupG and endA genes were inactivated independently and in combination. The performance of the mutant strains was evaluated in shake flasks for the production of a 6.1 kb plasmid bearing an antigen gene against mumps. The best producer strain was cultivated in lab-scale bioreactors using 100 g/L of glucose to achieve HCDC in batch mode. For comparison, the widely used commercial strain DH5α, carrying the same plasmid, was also cultivated under the same conditions. RESULTS: The various mutations tested had different effects on the specific growth rate, glucose uptake rate, and pDNA yields (YP/X). The triple mutant VH33 Δ (recA deoR nupG) accumulated low amounts of acetate and resulted in the best YP/X (4.22 mg/g), whereas YP/X of strain VH33 only reached 1.16 mg/g. When cultivated at high glucose concentrations, the triple mutant strain produced 186 mg/L of pDNA, 40 g/L of biomass and only 2.2 g/L of acetate. In contrast, DH5α produced only 70 mg/L of pDNA and accumulated 9.5 g/L of acetate. Furthermore, the supercoiled fraction of the pDNA produced by the triple mutant was nearly constant throughout the cultivation. CONCLUSION: The pDNA concentration obtained with the engineered strain VH33 Δ (recA deoR nupG) is, to the best of our knowledge, the highest reported for a batch cultivation, and its supercoiled fraction remained close to 80%. Strain VH33 Δ (recA deoR nupG) and its cultivation using elevated glucose concentrations represent an attractive technology for fast and efficient pDNA production and a valuable alternative to fed-batch cultivations of commercial strains.
Asunto(s)
Escherichia coli/metabolismo , Plásmidos/metabolismo , Antígenos/genética , Antígenos/metabolismo , Biomasa , Reactores Biológicos/microbiología , Escherichia coli/crecimiento & desarrollo , Proteínas de Escherichia coli/genética , Técnicas de Inactivación de Genes , Ingeniería Genética , Glucosa/metabolismo , Proteínas de Transporte de Membrana/genética , Virus de la Parotiditis/metabolismo , Plásmidos/genética , Rec A Recombinasas/genética , Proteínas Represoras/genética , Vacunas de ADN/biosíntesisRESUMEN
Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries.
Asunto(s)
Vacuna contra la Brucelosis , Brucella abortus/efectos de los fármacos , Brucelosis/prevención & control , Complicaciones Infecciosas del Embarazo/prevención & control , Vacunas Atenuadas , Vacunas de Subunidad , Vacunas Sintéticas , Secuencia de Aminoácidos , Animales , Argentina , Brasil , Vacuna contra la Brucelosis/administración & dosificación , Vacuna contra la Brucelosis/biosíntesis , Vacuna contra la Brucelosis/síntesis química , Brucella abortus/fisiología , Brucelosis/inmunología , Brucelosis/microbiología , Bovinos , Femenino , Regulación Gubernamental , Humanos , Ratones , Datos de Secuencia Molecular , Embarazo , Complicaciones Infecciosas del Embarazo/inmunología , Ovinos , Resultado del Tratamiento , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/biosíntesis , Vacunas Atenuadas/síntesis química , Vacunas de ADN/administración & dosificación , Vacunas de ADN/biosíntesis , Vacunas de ADN/síntesis química , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/biosíntesis , Vacunas de Subunidad/síntesis química , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/biosíntesis , Vacunas Sintéticas/genéticaRESUMEN
A tuberculose (TB) é responsável por dois milhões de mortes a cada ano, apesar daampla utilização da vacina BCG (Bacilo Calmette-Guérin). Embora essa vacina nãoproteja contra a TB pulmonar no adulto, protege contra as formas graves da TB nainfância. Para muitos autores, a imunização heteróloga (prime-boost) talvezseja uma das estratégias mais importantes e realistas para o controle da TB,principalmente nos países endêmicos. Muitos estudos têm demonstrado que aimunização com BCG seguido de reforço com vacina gênica (genes de M.tuberculosis) induz melhor proteção contra TB do que somente a vacina BCG. Alémdisso, a estratégia prime-boost utilizando microesferas biodegradáveis pareceser uma imunização promissora para estimular a resposta imune de longa duração.A glicoproteína APA foi identificada como importante antígeno imunodominante,induzindo níveis significativos de proteção contra M. tuberculosis. Assim, esteestudo teve como objetivo avaliar a eficácia protetora da imunização heteróloga emmodelo experimental de TB. Para isso, camundongos BALB/c foram imunizados porvia subcutânea com BCG seguido de um reforço por via intramuscular com aformulação vacinal contendo apa e DMT co-encapsuladosem microesferas (BCG/APA). Essa estratégia prime-boost foi eficiente na indução daresposta imune protetora à infecção por M. tuberculosis, caracterizada pela reduçãosignificativa do número de bacilos no pulmão destes animais na fase mais tardia dainfecção (70 dias após desafio). Além de ser significativamente mais imunogênciaque a vacina BCG, permitiu uma melhor preservação do parênquima pulmonar, comredução do número e tamanho dos granulomas, limitando a extensão da injúriatecidual induzida pela infecção e restringindo a inflamação no tecido alveolar. Apotencialização do efeito protetor da vacina BCG induzida pelo reforço com a vacinapVAXapa+DMT-Me sugere que a estratégia utilizada pode ser importante para aprevenção da TB...
Tuberculosis (TB) is responsible for two millions of deaths each year despite thewidespread use of BCG vaccine (Bacillus Calmette-Guérin). Although this vaccinedoes not protect against adult pulmonary TB, it is protective against severe forms ofchildhood TB. For many authors, heterologous prime-boost regimen is perhaps themost realistic strategy for future TB control, especially in endemic countries. Manystudies have demonstrated that BCG-prime DNA-(M. tuberculosis genes)-boosterinduce greater protection against TB than BCG alone. APA glycoprotein has beenidentified as major immunodominant antigen and induces significant levels ofprotection against M. tuberculosis. Moreover, prime-boost strategy by usingbiodegradable microspheres seems to be a promising immunization to stimulate longlasting immune response. Thus, this study had as aim to investigate the immuneprotection against M. tuberculosis challenge in mice based on BCG priming and DNAvaccine boosting. For that, BALB/c mice were inoculated subcutaneously with aheterologous BCG priming-DNA boosting immunization using pVAXapa and TDM coencapsulatedin microspheres (BCG/APA), intramuscularly. This prime-boost strategywas effective in inducing protective immune response against M. tuberculosisinfection, characterized by significant lower numbers of bacilli in the lungs of theseanimals, in the late phase of infection (70 days after infection). In addition to beingsignificantly more immunogenic than BCG, it allowed better preservation of the lungparenchyma and reduction in the number and size of granulomas, limiting the extentof lung injury induced by infection and inflammation in the alveolar tissue. Theimprovement of the protective effect of BCG vaccine mediated by pVAXapa boostersuggests that our strategy can be important in the treatment for prevention of TB...
Asunto(s)
Ratones , Vacuna BCG , Microesferas , Vacunas contra la Tuberculosis , Tuberculosis/epidemiología , Tuberculosis/inmunología , Vacunas de ADN/biosíntesisRESUMEN
HSV-1 amplicon vectors encoding heterologous antigens were capable to mediate in situ generation of protein synthesis and to generate a specific immune response to the corresponding antigens. In this study, foot-and-mouth disease (FMD) virus antigens were used to generate a genetic vaccine prototype. The amplicons were designed to provide a high safety profile as they do not express any HSV-1 genes when packaged using a helper virus-free system, and they are able to encapsidate several copies of the transgene or allow the simultaneous expression of different genes. Virus-like particles were produced after cell processing of the delivered DNA. Inoculation of mice with 5 × 10(5) transducing units of amplicon vectors resulted in FMDV-specific humoral responses in the absence of adjuvants, which were dependent on the in situ de novo production of the vector-encoded antigens. Challenge of mice vaccinated with these amplicons with a high dose of live virus, resulted in partial protection, with a significant reduction of viremia. This work highlights the potential use of a HSV-1 amplicon vector platform for generation of safe genetic vaccines.